Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with <sup>131</sup>I-metaiodobenzylguanidine

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Opening Hours
Collections
Help Via Email

Electronic Information Resources

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with ¹³¹I-metaiodobenzylguanidine

详细信息查看全文

作者：Kelly E. Huibregtse^a ; ¹ ; ^{kelly.huibregtse@ucsf.edu" class="auth_mail" title="E-mail the corresponding author} ; Kieuhoa T. Vo^b ; ^{Kieuhoa.Vo@ucsf.edu" class="auth_mail" title="E-mail the corresponding author} ; Steven G. DuBois^c ; ^{Steven_Dubois@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author} ; Stephanie Fetzko^d ; ^{fetzko@bcm.edu" class="auth_mail" title="E-mail the corresponding author} ; John Neuhaus^e ; ^{John.Neuhaus@ucsf.edu" class="auth_mail" title="E-mail the corresponding author} ; Vandana Batra^f ; ^{Batrav@email.chop.edu" class="auth_mail" title="E-mail the corresponding author} ; John M. Maris^f ; ^{Maris@email.chop.edu" class="auth_mail" title="E-mail the corresponding author} ; Brian Weiss^g ; ^{Brian.Weiss@cchmc.org" class="auth_mail" title="E-mail the corresponding author} ; Araz Marachelian^h ; ^{AMarachelian@chla.usc.edu" class="auth_mail" title="E-mail the corresponding author} ; Greg A. Yanikⁱ ; ^{gyanik@med.umich.edu" class="auth_mail" title="E-mail the corresponding author} ; Katherine K. Matthay^b ; ^{kate.matthay@ucsf.edu" class="auth_mail" title="E-mail the corresponding author}
关键词：Neuroblastoma ; Paediatrics ; Cancer ; MIBG ; I-metaiodobenzylguanidine ; SMN ; Second malignancy ; Chemotherapy ; Solid tumour ; Survivorship
刊名：European Journal of Cancer
出版年：2016
出版时间：October 2016
年：2016
卷：66
期：Complete
页码：144-152
全文大小：368 K

文摘

class="label">•: Multi-institutional review of neuroblastoma patients treated with iodine-131 metaiodobenzylguanidine (¹³¹I-MIBG) therapy.
class="label">•: Competing risk approach used to find cumulative incidence of second malignant neoplasm (SMN) from first MIBG.
class="label">•: Cumulative risk of SMN after MIBG therapy was 14% at 10 years.
class="label">•: Results similar to risk after myeloablative therapy; no dose-dependent increase.

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.